Cellectar Biosciences, Inc. — Q3 2023 Form 10-Q
Business context and reporting period. This clinical-stage biopharmaceutical company develops cancer therapies using its phospholipid drug conjugate platform. The report covers the three and nine months ended September 30, 2023. Its lead candidate, iopofosine I 131, was being studied in several cancer indications; the pivotal CLOVER-WaM study was fully enrolled, with topline data expected in January 2024. The company reported no revenue.
Financial results and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| R&D expense | $7.31 million (2022: $5.38 million) | $20.28 million (2022: $13.77 million) |
| General and administrative expense | $2.10 million (2022: $2.44 million) | $6.14 million (2022: $7.63 million) |
| Net loss | $13.73 million (2022: $7.81 million) | $30.53 million (2022: $21.39 million) |
| Basic and diluted loss per share | $1.21 (2022: $1.28) | $2.71 (2022: $3.50) |
- Operating cash used was $22.78 million in the first nine months of 2023, versus $17.81 million a year earlier. Investing activities used $0.60 million; financing provided $22.50 million. Cash declined $0.88 million to $18.99 million.
- At September 30, cash and cash equivalents were $18.99 million; current assets were $20.11 million and current liabilities $16.47 million. Total liabilities were $16.98 million. No borrowings are reported; lease liabilities totaled approximately $0.57 million.
- Accumulated deficit was $210.03 million. Stockholders’ equity was negative $13.35 million, with $17.92 million of Series E-1 preferred stock classified as mezzanine equity.
- The company said available cash was expected to fund basic budgeted operations into the second quarter of 2024. It also stated that additional financing is needed to execute its plan and that this uncertainty raises substantial doubt about its ability to continue as a going concern within one year of issuance of the financial statements.
Material changes versus the prior comparable period
- Quarterly R&D expense rose 36%; for the nine-month period it rose 47%. Management attributed the increase mainly to manufacturing and production-sourcing costs, with higher clinical activity and personnel/professional costs also contributing over nine months. NCI grant funding reduced R&D expense by approximately $1.31 million in the nine-month period.
- G&A declined 14% for the quarter and 20% for the nine-month period, primarily due to lower professional fees.
- Net loss increased substantially, including $4.37 million of warrant-related expense in 2023: $0.47 million issuance expense and a $3.90 million fair-value remeasurement loss. The warrant liability was valued at $8.60 million at quarter-end.
- In September, the company raised $24.5 million gross, or approximately $22.15 million net, through a private placement of Series E preferred stock and warrants. Stockholders approved the transaction on October 25, 2023; the approval removed the Series E-1 redemption feature. Warrants and potential preferred-stock conversions create significant potential dilution.
Outlook, risks, contingencies, and unusual items
- No formal financial guidance was provided. Management expects continued operating losses and plans to pursue equity or debt financing, a strategic transaction, or other funding alternatives; there is no assurance it will obtain funding.
- Clinical development and regulatory outcomes remain uncertain. The filing describes adverse events including cytopenias and fatigue across iopofosine studies, and reports at least one infection-related fatality possibly attributed to treatment.
- Management identified a material weakness in internal control over financial reporting related to valuation methodologies and assumptions for Level 3 instruments. Disclosure controls and procedures were deemed ineffective; remediation was in process. The filing says the weakness had not resulted in identified financial-statement misstatements.
- The company cited its ability to meet Nasdaq continued-listing standards as a liquidity-related uncertainty. A previously disclosed intellectual-property lawsuit was resolved in 2022, with the company securing an irrevocable, non-exclusive license to the disputed patents.
Important facts for investors to verify
- Whether additional financing is secured before the stated cash runway ends, and the terms and dilution associated with any financing.
- Topline CLOVER-WaM results expected in January 2024, and subsequent regulatory or clinical milestones for iopofosine.
- The scale and potential exercise or conversion of outstanding warrants and preferred securities; the filing lists 28.67 million shares issuable upon exercise of warrants as of September 30.
- Progress in remediating the Level 3 valuation control weakness and whether controls are later determined effective.
- Cash burn, manufacturing and clinical-trial costs, and whether the company’s runway assumptions remain current.